Nuvectis Pharma Inc. (NVCT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
5.48
-0.16 (-2.84%)
At close: Jan 15, 2025, 2:29 PM
Company Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases.
The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma Inc.
Country | United States |
IPO Date | Feb 4, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Ron Bentsur M.B.A. |
Contact Details
Address: 1 Bridge Plaza Fort Lee, New Jersey United States | |
Website | https://www.nuvectis.com |
Stock Details
Ticker Symbol | NVCT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001875558 |
CUSIP Number | 67080T108 |
ISIN Number | US67080T1088 |
Employer ID | 86-2405608 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Ron Bentsur M.B.A. | Co-Founder, Chairman, Chief Executive Officer & President |
Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive Vice President, Chief Scientific & Business Officer |
Michael Carson CPA | Vice President of Finance |
Shay Shemesh | Co-Founder, Executive Vice President, Chief Development & Operations Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | S-8 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 16, 2024 | 4/A | [Amend] Filing |
Dec 16, 2024 | 4 | Filing |
Nov 20, 2024 | 4 | Filing |
Nov 18, 2024 | 4 | Filing |